COVID-19: Centre's expert panel allows clinical trials for third dose of Covaxin

Bharat Biotech presented amendments to the subject expert committee of the Drugs Controller General of India (DCGI) in the approved Phase 2 clinical trial protocol for administration of booster dose six months after second dose.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3sWGEhL
via IFTTT